Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone615-255-0068
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.74 million
Profitability
Miscellaneous
Employees80
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions
What is Cumberland Pharmaceuticals' stock symbol?
Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."
How were Cumberland Pharmaceuticals' earnings last quarter?
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) issued its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.14. The specialty pharmaceutical company had revenue of $8.49 million for the quarter, compared to analyst estimates of $9.16 million. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 9.87%. View Cumberland Pharmaceuticals' Earnings History.
When is Cumberland Pharmaceuticals' next earnings date?
What price target have analysts set for CPIX?
0 brokerages have issued twelve-month target prices for Cumberland Pharmaceuticals' stock. Their forecasts range from $10,000,000.00 to $0.00. On average, they expect Cumberland Pharmaceuticals' share price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for Cumberland Pharmaceuticals.
What is the consensus analysts' recommendation for Cumberland Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." View Analyst Ratings for Cumberland Pharmaceuticals.
Has Cumberland Pharmaceuticals been receiving favorable news coverage?
Media coverage about CPIX stock has trended negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cumberland Pharmaceuticals.
Are investors shorting Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals saw a decrease in short interest in the month of July. As of July 15th, there was short interest totalling 87,000 shares, a decrease of 7.8% from the June 15th total of 94,400 shares. Based on an average daily volume of 24,600 shares, the short-interest ratio is presently 3.5 days. Approximately 1.0% of the shares of the stock are short sold. View Cumberland Pharmaceuticals' Current Options Chain.
Who are some of Cumberland Pharmaceuticals' key competitors?
Some companies that are related to Cumberland Pharmaceuticals include Organogenesis (ORGO), Arcus Biosciences (RCUS), BIOFRONTERA AG/ADR (BFRA), Akorn (AKRX), Rigel Pharmaceuticals (RIGL), ProQR Therapeutics (PRQR), XBiotech (XBIT), CV Sciences (CVSI), Assembly Biosciences (ASMB), BELLUS Health (BLUSF), Progenics Pharmaceuticals (PGNX), Kadmon (KDMN), Mirum Pharmaceuticals (MIRM), Theratechnologies (THERF) and OvaScience (OVAS).
What other stocks do shareholders of Cumberland Pharmaceuticals own?
Who are Cumberland Pharmaceuticals' key executives?
Cumberland Pharmaceuticals' management team includes the folowing people:
- Mr. A. J. Kazimi, Founder, Chairman, Pres & CEO (Age 61)
- Mr. Michael P. Bonner, CFO and Sr. Director of Fin. & Accounting (Age 42)
- Mr. Leo B. Pavliv, Exec. VP of Operations & Chief Devel. Officer (Age 58)
- Mr. James Lowrance Herman, Sr. VP of National Accounts & Chief Compliance Officer (Age 64)
- Mr. Martin E. Cearnal, Exec. VP of Marketing & Sales, Chief Commercial Officer and Director (Age 74)
Who are Cumberland Pharmaceuticals' major shareholders?
Cumberland Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (5.61%), Renaissance Technologies LLC (2.84%), BlackRock Inc. (2.14%), Acadian Asset Management LLC (0.67%) and Bailard Inc. (0.09%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, Caroline Young, Gordon R Bernard, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Institutional Ownership Trends for Cumberland Pharmaceuticals.
Which major investors are selling Cumberland Pharmaceuticals stock?
Which major investors are buying Cumberland Pharmaceuticals stock?
CPIX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Bailard Inc. and Acadian Asset Management LLC. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals.
How do I buy shares of Cumberland Pharmaceuticals?
Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cumberland Pharmaceuticals' stock price today?
One share of CPIX stock can currently be purchased for approximately $5.63.
How big of a company is Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals has a market capitalization of $86.53 million and generates $40.74 million in revenue each year. The specialty pharmaceutical company earns $-6,960,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. Cumberland Pharmaceuticals employs 80 workers across the globe.View Additional Information About Cumberland Pharmaceuticals.
What is Cumberland Pharmaceuticals' official website?
How can I contact Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]
MarketBeat Community Rating for Cumberland Pharmaceuticals (NASDAQ CPIX)
MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
